Monitor for any subsequent filings that might indicate changes in board dynamics or executive compensation trends, though this specific filing represents standard annual governance procedures.
PTCT drugs
PTCT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 21 $70.63entry
- T+1 · 7mo ago +0.31%α −0.71% · $70.85
- T+5 · 7mo ago −0.52%α −1.61% · $70.26
- T+20 · 6mo ago −0.68%α −5.59% · $70.15
- T+60 · 4mo ago +11.17%α +4.27% · $78.52
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PTC Therapeutics is holding its 2026 annual meeting to elect four Class I directors, including Jessica Chutter who was recently appointed to the board. This filing is a definitive proxy statement soliciting shareholder votes on director elections, auditor ratification, and executive compensation. The filing follows a recent 8-K filing announcing Chutter's appointment and other board/executive changes, suggesting these materials are part of an ongoing governance process.
Key Financial Metrics
Key Facts
- PTC Therapeutics is holding its 2026 annual meeting to elect four Class I directors: Jessica Chutter, Matthew B. Klein, Stephanie S. Okey, and Jerome B. Zeldis
- The proxy statement solicits votes on three proposals: election of directors, ratification of Ernst & Young as auditors, and approval of executive compensation
- This filing follows a March 25, 2026 Form 8-K announcing Jessica Chutter's appointment to the board and other executive changes
- The filing is routine corporate governance documentation for the annual shareholder meeting
Financial Impact
No direct financial impact - this is a routine governance filing
Risk Factors
- Potential for shareholder activism if there are concerns about board composition or executive pay
- Risk of low shareholder turnout for the vote
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-045533 |
| Document: 0001104659-26-045533-index-headers.html | 0001104659-26-045533 |
| Document: 0001104659-26-045533-index.html | 0001104659-26-045533 |
| Document: 0001104659-26-045533.txt | 0001104659-26-045533 |
Track record
29 reports on PTCT
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +19.01% at T+60 after the Apr 28, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.09 Now $60.97 −1.80% settles Nov 17
- Nov 16, 2026today 144 Neutral 2/10 Entry $62.10 Now $60.97 −1.82% settles Nov 17
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $63.45 Now $60.97 −3.91% settles Nov 17
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $64.14 to $64.91 Now $60.97 −4.94% ▲ +1.20% −0.12% vs SPY
- Nov 3, 202613d ago 8-K Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 3, 202613d ago Press Release Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $68.12 to $68.97 Now $60.97 +10.50% ▼ −1.25% +0.40% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $59.97 to $60.88 Now $60.97 +1.67% ▲ +1.52% +2.00% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $63.02 to $64.46 Now $60.97 −3.25% ▲ +2.29% +2.67% vs SPY
- Oct 16, 20264w ago Insider Cluster Neutral 3/10 Entry $61.53 to $62.92 Now $60.97 −0.91% ▲ +2.26% +1.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers